vs

Side-by-side financial comparison of Coeptis Therapeutics Holdings, Inc. (COEP) and Palladyne AI Corp. (PDYN). Click either name above to swap in a different company.

Palladyne AI Corp. is the larger business by last-quarter revenue ($1.7M vs $862.0K, roughly 1.9× Coeptis Therapeutics Holdings, Inc.). Palladyne AI Corp. runs the higher net margin — -89.9% vs -146.5%, a 56.6% gap on every dollar of revenue.

Coeptis Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapies, including cell therapy and antibody-based treatment candidates, to address unmet medical needs for patients with hard-to-treat malignancies. It primarily operates in the U.S., advancing its product pipeline across multiple oncology segments.

Palladyne AI Corp. is an American company known for most of its existence primarily as a developer of robots. Palladyne was founded in 1983 as Sarcos Research Corporation. In 2023, Sarcos shifted its business focus to the development of artificial intelligence (AI) software for robotic applications, discontinuing its hardware operations. In March 2024, the company changed its name to Palladyne AI.

COEP vs PDYN — Head-to-Head

Bigger by revenue
PDYN
PDYN
1.9× larger
PDYN
$1.7M
$862.0K
COEP
Higher net margin
PDYN
PDYN
56.6% more per $
PDYN
-89.9%
-146.5%
COEP

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
COEP
COEP
PDYN
PDYN
Revenue
$862.0K
$1.7M
Net Profit
$-1.3M
$-1.5M
Gross Margin
94.8%
15.6%
Operating Margin
-230.6%
-560.7%
Net Margin
-146.5%
-89.9%
Revenue YoY
118.3%
Net Profit YoY
55.1%
97.2%
EPS (diluted)
$0.05
$-0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
COEP
COEP
PDYN
PDYN
Q4 25
$862.0K
$1.7M
Q3 25
$237.4K
$860.0K
Q2 25
$200.7K
$1.0M
Q1 25
$62.9K
$1.7M
Q4 24
$0
$761.0K
Q3 24
$0
$871.0K
Q2 24
$0
$2.7M
Q1 24
$0
$3.4M
Net Profit
COEP
COEP
PDYN
PDYN
Q4 25
$-1.3M
$-1.5M
Q3 25
$-2.9M
$-3.7M
Q2 25
$-4.3M
$-7.5M
Q1 25
$-3.4M
$22.8M
Q4 24
$-2.8M
Q3 24
$-1.8M
$-7.1M
Q2 24
$-3.0M
$-5.3M
Q1 24
$-3.0M
$-7.2M
Gross Margin
COEP
COEP
PDYN
PDYN
Q4 25
94.8%
15.6%
Q3 25
81.0%
46.4%
Q2 25
77.5%
53.3%
Q1 25
28.2%
79.4%
Q4 24
27.2%
Q3 24
45.0%
Q2 24
79.0%
Q1 24
45.2%
Operating Margin
COEP
COEP
PDYN
PDYN
Q4 25
-230.6%
-560.7%
Q3 25
-1043.2%
-937.8%
Q2 25
-2252.9%
-797.4%
Q1 25
-6452.6%
-405.3%
Q4 24
Q3 24
-838.0%
Q2 24
-213.3%
Q1 24
-213.7%
Net Margin
COEP
COEP
PDYN
PDYN
Q4 25
-146.5%
-89.9%
Q3 25
-1220.8%
-434.9%
Q2 25
-2159.9%
-737.6%
Q1 25
-5440.9%
1330.9%
Q4 24
Q3 24
-814.7%
Q2 24
-196.2%
Q1 24
-210.1%
EPS (diluted)
COEP
COEP
PDYN
PDYN
Q4 25
$0.05
$-0.02
Q3 25
$-0.58
$-0.09
Q2 25
$-1.17
$-0.20
Q1 25
$-1.11
$0.55
Q4 24
$-5.35
Q3 24
$-0.05
$-0.27
Q2 24
$-0.08
$-0.20
Q1 24
$-0.08
$-0.28

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
COEP
COEP
PDYN
PDYN
Cash + ST InvestmentsLiquidity on hand
$676.6K
$47.1M
Total DebtLower is stronger
$150.0K
Stockholders' EquityBook value
$13.6M
$74.7M
Total Assets
$16.2M
$95.7M
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
COEP
COEP
PDYN
PDYN
Q4 25
$676.6K
$47.1M
Q3 25
$421.7K
$57.1M
Q2 25
$990.6K
$62.7M
Q1 25
$46.6M
Q4 24
$40.1M
Q3 24
$21.3M
Q2 24
$25.8M
Q1 24
$31.8M
Total Debt
COEP
COEP
PDYN
PDYN
Q4 25
$150.0K
Q3 25
$150.0K
Q2 25
$150.0K
Q1 25
Q4 24
$150.0K
Q3 24
$1.7M
Q2 24
$1.7M
Q1 24
$2.3M
Stockholders' Equity
COEP
COEP
PDYN
PDYN
Q4 25
$13.6M
$74.7M
Q3 25
$10.4M
$51.8M
Q2 25
$6.1M
$53.8M
Q1 25
$6.5M
$28.3M
Q4 24
$3.4M
$-9.5M
Q3 24
$4.8M
$23.4M
Q2 24
$-442.6K
$29.8M
Q1 24
$-1.1M
$34.2M
Total Assets
COEP
COEP
PDYN
PDYN
Q4 25
$16.2M
$95.7M
Q3 25
$14.2M
$72.9M
Q2 25
$12.2M
$78.3M
Q1 25
$13.5M
$63.3M
Q4 24
$8.9M
$56.3M
Q3 24
$9.0M
$38.7M
Q2 24
$4.2M
$45.1M
Q1 24
$3.9M
$50.4M
Debt / Equity
COEP
COEP
PDYN
PDYN
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
Q4 24
0.04×
Q3 24
0.35×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
COEP
COEP
PDYN
PDYN
Operating Cash FlowLast quarter
$-8.6M
$-8.5M
Free Cash FlowOCF − Capex
$-8.7M
FCF MarginFCF / Revenue
-526.2%
Capex IntensityCapex / Revenue
14.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
COEP
COEP
PDYN
PDYN
Q4 25
$-8.6M
$-8.5M
Q3 25
$-2.2M
$-6.3M
Q2 25
$-2.4M
$-5.3M
Q1 25
$-2.4M
$-7.5M
Q4 24
$-6.6M
$-22.6M
Q3 24
$-1.9M
$-4.5M
Q2 24
$-1.4M
$-5.8M
Q1 24
$-1.9M
$-7.2M
Free Cash Flow
COEP
COEP
PDYN
PDYN
Q4 25
$-8.7M
Q3 25
$-6.7M
Q2 25
Q1 25
$-7.6M
Q4 24
$-22.9M
Q3 24
$-4.5M
Q2 24
$-5.9M
Q1 24
$-7.3M
FCF Margin
COEP
COEP
PDYN
PDYN
Q4 25
-526.2%
Q3 25
-776.0%
Q2 25
Q1 25
-445.0%
Q4 24
-3008.1%
Q3 24
-517.8%
Q2 24
-218.9%
Q1 24
-212.1%
Capex Intensity
COEP
COEP
PDYN
PDYN
Q4 25
14.2%
Q3 25
44.7%
Q2 25
0.0%
Q1 25
5.4%
Q4 24
34.8%
Q3 24
1.4%
Q2 24
5.3%
Q1 24
1.8%
Cash Conversion
COEP
COEP
PDYN
PDYN
Q4 25
Q3 25
Q2 25
Q1 25
-0.33×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons